Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1

Stem Cells

Volumn 32, Issue 9, 2014, Pages 2309-2323

  Choi, Dong Soon ^a   Blanco, Elvin ^b   Kim, Yoo Shin ^b   Rodriguez, Angel A ^a   Zhao, Hong ^b,c   Huang, Tim Hui Ming ^d   Chen, Chun Liang ^d   Jin, Guangxu ^c   Landis, Melissa D ^a   Burey, Lacey A ^a   Qian, Wei ^a   Granados, Sergio M ^a   Dave, Bhuvanesh ^a   Wong, Helen H ^a   Ferrari, Mauro ^b,c   Wong, Stephen T C ^b,c   Chang, Jenny C ^a,c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Autophagy; Breast cancer stem cells; Chloroquine; DNMT1; Jak2

Indexed keywords

ARSENIC TRIOXIDE; AURANOFIN; BETA CATENIN; CASPASE 3; CD24 ANTIGEN; CHLOROQUINE; DNA METHYLTRANSFERASE 1; JANUS KINASE 2; PACLITAXEL; PROTEIN KINASE B; PROTEIN P53; SONIC HEDGEHOG PROTEIN; STAT PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; WNT PROTEIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; JAK2 PROTEIN, HUMAN;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CELL RENEWAL; CELL SUBPOPULATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG REPOSITIONING; GENE EXPRESSION; GENE MAPPING; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; ANIMAL; DRUG EFFECTS; FEMALE; METABOLISM; NUDE MOUSE; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; AUTOPHAGY; CELL LINE, TUMOR; CHLOROQUINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FEMALE; HUMANS; JANUS KINASE 2; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84906283311     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1746     Document Type: Article

References (45)

1. Foulkes WD, Smith IE, Reis-Filho JS,. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
2. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
3. Idowu MO, Kmieciak M, Dumur C, et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012; 43: 364-373.
4. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820-13825.
5. Marotta LL, Almendro V, Marusyk A, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest 2011; 121: 2723-2735.
6. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-659.
7. Janku F, McConkey DJ, Hong DS, et al. Autophagy as a target for anticancer therapy. Nat Rev 2011; 8: 528-539.
8. Kenific CM, Thorburn A, Debnath J., Autophagy and metastasis: Another double-edged sword. Curr Opin Cell Biol 2010; 22: 241-245.
9. Martinez-Outschoorn UE, Lin Z, Ko YH, et al. Understanding the metabolic basis of drug resistance: Therapeutic induction of the Warburg effect kills cancer cells. Cell Cycle 2011; 10: 2521-2528.
10. Sanchez CG, Penfornis P, Oskowitz AZ, et al. Activation of autophagy in mesenchymal stem cells provides tumor stromal support. Carcinogenesis 2011; 32: 964-972.
11. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, et al. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle 2011; 10: 3871-3885.
12. Gong C, Bauvy C, Tonelli G, et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene 2013; 32: 2261-2272.
13. Sotelo J, Briceno E, Lopez-Gonzalez MA,. Adding chloroquine to conventional treatment for glioblastoma multiforme: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006; 144: 337-343.
14. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109-1123.
15. Jin G, Fu C, Zhao H, et al. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res 2012; 72: 33-44.
16. Zhao H, Jin G, Cui K, et al. Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases. Cancer Res 2013; 73: 6149-6163.
17. Schott AF, Landis MD, Dontu G, et al. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res 2013; 19: 1512-1524.
18. Kim JH, Choi DS, Lee OH, et al. Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events. Blood 2011; 118: 2622-2631.
19. Rozen S, Skaletsky H,. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365-386.
20. Langmead B, Trapnell C, Pop M, et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009; 10: R25.
21. Feng J, Liu T, Qin B, et al. Identifying ChIP-seq enrichment using MACS. Nat Protocols 2012; 7: 1728-1740.
22. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69: 1302-1313.
23. Hu Y, Smyth GK,. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70-78.
24. Zhou J, Wulfkuhle J, Zhang H, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 2007; 104: 16158-16163.
25. Ungureanu D, Saharinen P, Junttila I, et al. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 2002; 22: 3316-3326.
26. Kershaw NJ, Murphy JM, Liau NP, et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 2013; 20: 469-476.
27. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29-35.
28. He B, You L, Uematsu K, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 2003; 100: 14133-14138.
29. Shao Z, Zhang Y, Yuan GC, et al. MAnorm: A robust model for quantitative comparison of ChIP-Seq data sets. Genome Biol 2012; 13: R16.
30. Tabas-Madrid D, Nogales-Cadenas R, Pascual-Montano A,. GeneCodis3: A non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res 2012; 40: W478-483.
31. Nogales-Cadenas R, Carmona-Saez P, Vazquez M, et al. GeneCodis: Interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res 2009; 37: W317-322.
32. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
33. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res 2006; 8: R59.
34. Liu H, Patel MR, Prescher JA, et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA 2010; 107: 18115-18120.
35. Merlos-Suarez A, Barriga FM, Jung P, et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011; 8: 511-524.
36. Kimura K, Yamada T, Matsumoto M, et al. Endoplasmic reticulum stress inhibits STAT3-dependent suppression of hepatic gluconeogenesis via dephosphorylation and deacetylation. Diabetes 2011; 61: 61-73.
37. Um HJ, Min KJ, Kim DE, et al. Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells. Biochem Biophys Res Commun 2012; 427: 24-29.
38. Gereige LM, Mikkola HK,. DNA methylation is a guardian of stem cell self-renewal and multipotency. Nat Genet 2009; 41: 1164-1166.
39. Mathews LA, Crea F, Farrar WL,. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation 2009; 78: 1-17.
40. Trowbridge JJ, Sinha AU, Zhu N, et al. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev 2012; 26: 344-349.
41. Lee H, Zhang P, Herrmann A, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci USA 2012; 109: 7765-7769.
42. Zhang Q, Wang HY, Marzec M, et al. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA 2005; 102: 6948-6953.
43. Alexander WS, Starr R, Metcalf D, et al. Suppressors of cytokine signaling (SOCS): Negative regulators of signal transduction. J Leukoc Biol 1999; 66: 588-592.
44. Elliott J, Johnston JA,. SOCS: Role in inflammation, allergy and homeostasis. Trends Immunol 2004; 25: 434-440.
45. Babon JJ, Nicola NA,. The biology and mechanism of action of suppressor of cytokine signaling 3. Growth Factors 2012; 30: 207-219.